1.785
前日終値:
$1.74
開ける:
$1.74
24時間の取引高:
439.45K
Relative Volume:
0.62
時価総額:
$64.91M
収益:
$832.00K
当期純損益:
$-135.12M
株価収益率:
-0.2931
EPS:
-6.09
ネットキャッシュフロー:
$-124.69M
1週間 パフォーマンス:
+0.85%
1か月 パフォーマンス:
-7.03%
6か月 パフォーマンス:
-68.90%
1年 パフォーマンス:
-81.56%
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
名前
Inovio Pharmaceuticals Inc
セクター
電話
(858) 410-3134
住所
660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA
INO を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
INO
Inovio Pharmaceuticals Inc
|
1.79 | 64.91M | 832.00K | -135.12M | -124.69M | -6.09 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
476.53 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.26 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
598.41 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
231.49 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
229.96 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-05-14 | 開始されました | Stephens | Overweight |
2024-01-25 | アップグレード | Oppenheimer | Perform → Outperform |
2022-11-09 | ダウングレード | Maxim Group | Buy → Hold |
2022-11-01 | ダウングレード | BofA Securities | Neutral → Underperform |
2022-07-19 | 再開されました | RBC Capital Mkts | Sector Perform |
2022-05-11 | ダウングレード | Oppenheimer | Outperform → Perform |
2022-01-21 | アップグレード | BofA Securities | Underperform → Neutral |
2021-12-29 | 再開されました | Jefferies | Hold |
2021-09-10 | ダウングレード | BofA Securities | Neutral → Underperform |
2021-06-24 | 開始されました | Jefferies | Hold |
2021-03-23 | 開始されました | BofA Securities | Neutral |
2021-02-12 | 開始されました | Oppenheimer | Outperform |
2020-11-17 | ダウングレード | ROTH Capital | Neutral → Sell |
2020-11-10 | アップグレード | ROTH Capital | Sell → Neutral |
2020-09-28 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
2020-09-28 | アップグレード | Maxim Group | Hold → Buy |
2020-07-01 | ダウングレード | Maxim Group | Buy → Hold |
2020-07-01 | ダウングレード | ROTH Capital | Neutral → Sell |
2020-06-29 | ダウングレード | H.C. Wainwright | Buy → Neutral |
2020-06-26 | ダウングレード | Stifel | Buy → Hold |
2020-05-21 | 開始されました | The Benchmark Company | Buy |
2020-04-30 | ダウングレード | ROTH Capital | Buy → Neutral |
2020-03-13 | ダウングレード | Piper Sandler | Overweight → Neutral |
2020-03-13 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
2019-12-19 | 開始されました | ROTH Capital | Buy |
2018-02-15 | 繰り返されました | Maxim Group | Buy |
2017-10-18 | 開始されました | RBC Capital Mkts | Outperform |
2017-09-06 | 開始されました | Citigroup | Buy |
2017-06-08 | アップグレード | Piper Jaffray | Neutral → Overweight |
2017-05-24 | 繰り返されました | Maxim Group | Buy |
2017-03-16 | アップグレード | Maxim Group | Hold → Buy |
2017-03-16 | ダウングレード | Piper Jaffray | Overweight → Neutral |
すべてを表示
Inovio Pharmaceuticals Inc (INO) 最新ニュース
Bet on These 5 Top-Ranked Stocks With Rising P/E - Nasdaq
Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2 Trial - ADVFN
Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Inovio Pharmaceuticals Inc. stock rises Friday, still underperforms market - MarketWatch
INOVIO to Highlight Breakthrough Immunotherapy Data at AACR Conference - MSN
INOVIO to Showcase Breakthrough Data on INO-3107 at Major Industry Conferences - MyChesCo
Inovio (INO) Upgraded to Buy: Here's What You Should Know - MSN
INOVIO Reports Inducement Grant Under Inducement Plan - MarketScreener
Next-generation Covid-19 vaccines currently being tested - Yahoo Finance
Inovio Pharmaceuticals Inc. stock rises Wednesday, still underperforms market - MarketWatch
INOVIO to Present at Upcoming Scientific Conferences | INO Stock News - GuruFocus
INOVIO to Present at Upcoming Scientific Conferences - Longview News-Journal
INOVIO's Breakthrough: 72% Success in HPV TreatmentMultiple Conference Spotlights - Stock Titan
Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Inovio stock touches 52-week low at $1.47 amid market challenges By Investing.com - Investing.com South Africa
Inovio stock touches 52-week low at $1.47 amid market challenges - Investing.com Australia
Inovio Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Inovio Pharmaceuticals to Host Third Quarter 2013 Earnings Webcast Live on Tuesday, November 12, 2013 - ACCESS Newswire
HPV Market to Reach $10.8 Bn, Globally, by 2031 at 12.4% CAGR | - openPR.com
Down -11.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Inovio (INO) - Yahoo Finance
Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Sector Update: Health Care - MarketScreener
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Inovio stock plunges to 52-week low at $1.74 amid market challenges By Investing.com - Investing.com South Africa
Inovio stock plunges to 52-week low at $1.74 amid market challenges - Investing.com Australia
Lassa Fever Market Anticipated to Expand Rapidly During 2024-2034, Says DelveInsight | Inovio Pharma - Barchart.com
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q4 2024 Earnings Call Transcript - Insider Monkey
INOVIO Reports Progress on INO-3107 and DNA Medicine, 2024 Financial Outcomes - MSN
Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Inovio’s SWOT analysis: dna firm’s stock faces crucial year ahead By Investing.com - Investing.com South Africa
DNA Vaccines Market and Their Impact on Global Health: Trends & - openPR.com
Inovio’s SWOT analysis: dna firm’s stock faces crucial year ahead - Investing.com
Inovio taking on Covid-19 again, almost 3 years after abandoning vaccine effort - Philadelphia Business Journal
Inovio aims for INO-3107 regulatory submission by mid-2025 while addressing key manufacturing issues - MSN
RBC Cuts Price Target on Inovio Pharmaceuticals to $5 From $6, Keeps Sector Perform, Speculative Risk - Marketscreener.com
Inovio Pharmaceuticals Inc (INO) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo
Inovio Pharmaceuticals Inc (INO) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus
Earnings call transcript: Inovio Q4 2024 sees narrowed losses, strategic focus - Investing.com Australia
Inovio Pharmaceuticals Inc (INO) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):